Rivaroxaban Tablet, Film Coated
Product Images NDC 31722-496

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 31722-496). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 3 (186d9028 88fd 4703 804c 2e3c98a5b007 02)

A pharmacokinetic chart showing fold change and 90% confidence intervals for Rivaroxaban. It compares Cmax and AUC parameters across different population descriptions including end-stage renal disease, various levels of renal impairment, age groups, body weight categories, and hepatic impairment, relative to normal/reference values.*

FDA Label Image

Image (186d9028 88fd 4703 804c 2e3c98a5b007 03)

A pharmacokinetic chart illustrating fold changes and 90% confidence intervals in Cmax and AUC for various interacting drugs relative to rivaroxaban alone. The chart categorizes drugs into combined P-gp and CYP3A4 inhibitors/inducers and other drugs, showing their impact on rivaroxaban exposure levels.*

FDA Label Image

Fig 9 (186d9028 88fd 4703 804c 2e3c98a5b007 04)

A forest plot chart comparing the primary efficacy outcome (composite of stroke, MI, or CV death) between Rivaroxaban and placebo groups. It displays hazard ratios with 95% confidence intervals across various subgroups including age, sex, region, weight, eGFR, MI history, stroke history, prior heart failure, baseline diabetes, and PAD. The chart visually indicates the relative risk favors Rivaroxaban in most subgroups.*

FDA Label Image

Figure 10 (186d9028 88fd 4703 804c 2e3c98a5b007 05)

A line chart depicting cumulative incidence rates (%) over days from randomization comparing Rivaroxaban (solid line) and placebo (dashed line). The chart includes numbers of subjects at risk for both groups at various time points and a hazard ratio comparison showing a hazard ratio of 0.74 (95% CI 0.65-0.86) for Rivaroxaban vs placebo.*

FDA Label Image

Figure 11 (186d9028 88fd 4703 804c 2e3c98a5b007 06)

A line graph showing the cumulative incidence rate (%) over days from randomization for treatment groups Rivaroxaban and Placebo. The graph compares the two groups' incidence rates up to 1095 days, with Rivaroxaban represented by a solid line and Placebo by a dashed line. It includes a hazard ratio (95% CI) of 0.85 (0.76, 0.96) for Rivaroxaban versus Placebo and a table listing the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 12 (186d9028 88fd 4703 804c 2e3c98a5b007 07)

A forest plot comparing the primary efficacy outcomes of Rivaroxaban versus placebo across various patient subgroups, including age, sex, weight, eGFR, baseline diabetes, CAD, randomization strata, clopidogrel use, history of revascularization, and critical limb ischemia categories. The plot displays hazard ratios with 95% confidence intervals and indicates areas favoring Rivaroxaban or placebo along the x-axis.*

FDA Label Image

2.5-180s Counts (2.5 180s Counts)

Rivaroxaban Tablets, USP 2.5 mg film-coated tablets label from Camber Pharmaceuticals, Inc. The label indicates 180 tablets in the package, with a prescription-only designation. It includes storage instructions, usual dosage advice, and manufacturer details for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc. A barcode and revision date (05/25) are also visible.*

FDA Label Image

2.5-60s Counts (2.5 60s Counts)

Label for Rivaroxaban Tablets, USP 2.5 mg oral film-coated tablets by Camber Pharmaceuticals, Inc. The label states each tablet contains 2.5 mg rivaroxaban, and the package contains 60 tablets. It includes storage instructions, medication guide reference, and manufacturer details for Ascent Pharmaceuticals and Camber Pharmaceuticals.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure diagram of the active ingredient Rivaroxaban, showing its molecular composition with rings, functional groups, and bonds as commonly depicted in pharmaceutical chemistry.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.